Makela V H, Kapur P A
Anesthesiology. 1987 Jun;66(6):792-7. doi: 10.1097/00000542-198706000-00013.
This study was designed to investigate the possibility of whether verapamil diminishes the effects of amrinone, whether amrinone can reverse verapamil-propranolol depression, and also to evaluate whether the order of administering the drugs would have any effect during 1.7-1.8% end-tidal isoflurane anesthesia in dogs. At 3-4-week intervals, each of six conditioned mongrel dogs (23 +/- 1 kg) received amrinone (A) (4 mg/kg plus 100 micrograms X kg-1 X min-1), verapamil (V) (200 micrograms/kg plus 7.5 micrograms X kg-1 X min-1) and propranolol (P) (150 micrograms/kg plus 0.8 microgram X kg-1 X min-1) in four different orders of administration: VAP, AVP, VPA, and PVA. Plasma levels achieved were 15 +/- 1 to 24 +/- 2 micrograms/ml for amrinone, 24 +/- 2 to 59 +/- 10 ng/ml for propranolol, and 81 +/- 10 to 163 +/- 17 ng/ml for verapamil, equivalent to high therapeutic (amrinone) and therapeutic (propranolol, verapamil) levels in humans. The results of this study show that amrinone is able to reverse many of the effects of verapamil (group VAP) and also many of the effects of verapamil-propranolol or propranolol-verapamil (groups VPA, PVA) combinations. Amrinone improved cardiac index, left ventricular dP/dtmax, pulmonary capillary wedge pressure, and central venous pressure without increasing catecholamines. However, mean arterial pressure remained decreased with decreased systemic vascular resistance, which necessitates careful consideration depending upon patient circumstances. The results also show that verapamil-propranolol can reverse the positive inotropic effects of amrinone (group AVP).(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在调查维拉帕米是否会减弱氨力农的作用、氨力农能否逆转维拉帕米 - 普萘洛尔所致的抑制作用,并评估在犬1.7 - 1.8%呼气末异氟烷麻醉期间给药顺序是否会产生任何影响。每隔3 - 4周,6只条件良好的杂种犬(体重23±1千克),以四种不同给药顺序接受氨力农(A)(4毫克/千克加100微克×千克⁻¹×分钟⁻¹)、维拉帕米(V)(200微克/千克加7.5微克×千克⁻¹×分钟⁻¹)和普萘洛尔(P)(150微克/千克加0.8微克×千克⁻¹×分钟⁻¹):VAP、AVP、VPA和PVA。所达到的血浆水平为:氨力农15±1至24±2微克/毫升,普萘洛尔24±2至59±10纳克/毫升,维拉帕米81±10至163±17纳克/毫升,相当于人类的高治疗水平(氨力农)和治疗水平(普萘洛尔、维拉帕米)。本研究结果表明,氨力农能够逆转维拉帕米的许多作用(VAP组)以及维拉帕米 - 普萘洛尔或普萘洛尔 - 维拉帕米组合的许多作用(VPA组、PVA组)。氨力农改善了心脏指数、左心室dp/dtmax、肺毛细血管楔压和中心静脉压,且未增加儿茶酚胺。然而,平均动脉压随着全身血管阻力降低而持续下降,这需要根据患者情况仔细考虑。结果还表明,维拉帕米 - 普萘洛尔可逆转氨力农的正性肌力作用(AVP组)。(摘要截断于250字)